All In Biotech

Drug Trial Radar · NCT00174642

Opposing Step-by-step Insulin Reinforcement to Intensified Strategy

Comparison of Three Therapeutic Strategies for Treating Type 2 Diabetes Mellitus Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs

Last checked: Nov 20, 2026Latest source record: Sep 15, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 811 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

811

Actual

Start

Dec 2004

Primary completion

Dec 2008

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Sep 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary objectives : * To show the non inferiority in terms of efficacy (HbA1c) of insulin glargine plus metformin combined with 1 to 3 bolus of insulin glulisine introduced progressively (Arm 2) compared with insulin glargine plus metformin combined with 3 bolus of insulin glulisine (Arm 1), in type 2 diabetes mellitus patients poorly controlled on basal insulin therapy with oral antidiabetic drugs. * To show the non inferiority in terms of efficacy (HbA1c) of insulin glargine plus metformin combined with 1 to 3 bolus of insulin glulisine introduced progressively (Arm 2) compared with insulin glargine plus metformin and insulin secretagogue (sulfonylurea or glinide) combined with 1 to 3 bolus of insulin glulisine introduced progressively (Arm 3), in type 2 diabetes mellitus patients poorly controlled on basal insulin therapy with oral antidiabetic drugs. Secondary objectives : * To compare between the 3 treatment groups: evolution of HbA1c over time, percentage of subjects with HbA1c \<= 7% at the end of the study, evolution of blood glucose profiles, incidence of hypoglycemia, insulin doses, evolution of body weight and treatment satisfaction.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Insulin GlargineDrug

    One daily injection in the evening. 100 U/ml

  • Insulin GlulisineDrug

    Given immediately before each of the three main meals. 100 U/ml

  • MetforminDrug

    At same dosages as the previous treatment

  • insulin secretagogueDrug

    sulfonylurea or glinide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HbA1cTime frame: From the beginning to the end of the study
  2. 24-hour blood glucose levelsTime frame: From the beginning to the end of the study
  3. symptomatic hypoglycemia (diurnal and nocturnal)Time frame: From the beginning to the end of the study
  4. Severe hypoglycemia (diurnal and nocturnal),Time frame: From the beginning to the end of the study
  5. Insulin dosesTime frame: From the beginning to the end of the study

Locations

18 sites in 18 countries. Site status is shown where the registry gives one.

  • Sanofi-Aventis

    Brussels, Belgium

  • Sanofi-Aventis

    Paris, France

  • Sanofi-Aventis

    Berlin, Germany

  • Sanofi-Aventis

    Athens, Greece

  • Sanofi-Aventis

    Budapest, Hungary

  • Sanofi-Aventis

    Dublin, Ireland

  • Sanofi-Aventis

    Milan, Italy

  • Sanofi-Aventis

    Vilnius, Lithuania

  • Sanofi-Aventis

    México, Mexico

  • Sanofi-Aventis

    Gouda, Netherlands

  • Sanofi-Aventis

    Warsaw, Poland

  • Sanofi-Aventis

    Moscow, Russia

  • Sanofi-Aventis

    Seoul, South Korea

  • Sanofi-Aventis

    Barcelona, Spain

  • Sanofi-Aventis

    Stockholm, Sweden

  • Sanofi-Aventis

    Taipei, Taiwan

  • Sanofi-Aventis

    Istanbul, Turkey (Türkiye)

  • Sanofi-Aventis

    Guildford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.